There are currently 2876 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
NCT04615013
Recruiting
The purpose of this Phase I study is to determine the recommended phase 2 dose (RP2D) and safety profile of NBTXR3 activated by radiation therapy with concurrent chemotherapy for the treatment of patients with esophageal adenocarcinoma. NBTXR3 is a drug that when activated by radiation therapy, may cause targeted destruction of cancer cells. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as oxaliplatin, fluorouracil, capecitabine, doceta... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Gastroesophageal Junction Adenocarcinoma, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Thoracic Esophagus Adenocarcinoma
Register for Updates
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
NCT04947319
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: Houston Methodist Research Institute (HMRI), Houston, Texas +1 locations
Conditions: Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
Register for Updates
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
NCT05079282
Recruiting
This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: MD Anderson, Houston, Texas
Conditions: Relapsed or Refractory T Cell Lymphoma
Register for Updates
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
NCT05091372
Recruiting
To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Myeloma Multiple
Register for Updates
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
NCT06218602
Recruiting
To find out if adding treatment with fecal microbiota transplantation (FMT) is effective at treating gut-related side effects of antibiotic treatment in participants who are receiving standard therapy with anti-CD19 chimeric antigen receptor T-cell (CAR-T cell) therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
NCT06445907
Recruiting
To learn about the safety and tolerability of the drug combination of Q702, azacitidine, and venetoclax when given to participants with relapsed/refractory AML.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia
Register for Updates
Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
NCT06660420
Recruiting
To find the highest tolerable dose and recommended dose of PRAME-TCR-NK cells that can be given to participants with recurrent and/or refractory melanoma. The safety and tolerability of PRAME-TCR-NK cells will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Phase 1, Recurrent Melanoma, Refractory Melanoma
Register for Updates
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898
Recruiting
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Oncology Consultants, Houston, Texas
Conditions: Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma, Biliary Tract Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer
Register for Updates
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
NCT06318897
Recruiting
To look at the effectiveness of the combination of pembrolizumab, carboplatin, and paclitaxel in participants with stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer
Register for Updates
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
NCT06414902
Recruiting
To learn if 18F-FAraG PET scans can find tumors in participants with esophageal cancer and predict a participant's response to treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Esophageal Cancer
Register for Updates
Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)
NCT06434337
Recruiting
To learn if new HPV tests can provide the same results as standard HPV tests. The findings from this study may aid in the development of new HPV tests that require less equipment and are more accessible.
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
05/30/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Human Papillomavirus
Register for Updates
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants
NCT06575192
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of ARTIA in adult participants undergoing immediate, two-stage, implant-based breast reconstruction post-mastectomy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: The University of Texas MD Anderson Cancer Center /ID# 264020, Houston, Texas
Conditions: Breast Reconstruction
Register for Updates